Our analysis revealed a significant increase of CD4+ and CD8+ T‐cell infiltration in tumours treated with PI3K/mTORi and PI3K/mTORi+PD‐1i, as compared to tumours treated with vehicle or PD‐1i alone (Figure S3A and B). Here, PIK3CB is linked to neoplasm.